FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Grais Linda					- 3. I	2. Issuer Name and Ticker or Trading Symbol     Corvus Pharmaceuticals, Inc. [ CRVS ]      3. Date of Earliest Transaction (Month/Day/Year)						(Che	eck all applic Director Officer	cable) r (give title	Person(s) to Iss 10% Ov Other (s	vner
(Last) (First) (Middle) C/O CORVUS PHARMACEUTICALS, INC.					12/06/2023  4. If Amendment, Date of Original Filed (Month/Day/Year)						6 In	below) below)  6. Individual or Joint/Group Filing (Check Applicable				
863 MIT	TEN ROA	D, SUITE 102			_  '	Aine	ridirierit, i	Date	or Originar i	ea (Monthi) De	ay/ rear)	Line	)	•	eporting Perso	·
(Street) BURLIN	IGAME C	'A	94010										Form fi Person		than One Repo	rting
(City)	?)	, 	(Zip)			Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										
1. Title of S	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  1. Title of Security (Instr. 3)  2. Transaction  2. Transaction  2. Deemed  3.  4. Securities Acquired (A) or  5. Amount of  6. Ownership  7. Nature												7. Nature			
Date (Month/Da			/Day/Ye	Execu ay/Year) if any		recution Date, any Ionth/Day/Year)	, Transaction Dispose Code (Instr. 5)		d Of (D) (Instr. 3, 4 and		Securities Beneficially Owned Following		Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership		
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		Instr. 4)	
		-							uired, Dis , options,				Owned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$1.64	12/06/2023			A		15,000		(1)	12/06/2033	Common Stock	15,000	\$0	15,000	D	

1. The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

> /s/ Leiv Lea, as Attorney-in-Fact for Linda S. Grais

12/08/2023 \*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.